Selected research
Market Structure
Global Anti-obesity Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-obesity Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-obesity Medicine include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Anti-obesity Medicine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-obesity Medicine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-obesity Medicine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Anti-obesity Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-obesity Medicine Segment by Company
Eisai
Novo Nordisk
Merck
Roche
Pfizer
GlaxoSmithKline
Vivus
Orexigen Therapeutics
Boehringer Ingelheim
Arena Pharmaceuticals
Amylin Pharmaceuticals
Alizyme
Anti-obesity Medicine Segment by Type
Prescription Drugs
OTC Drugs
Anti-obesity Medicine Segment by Application
Men
Women
Anti-obesity Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Anti-obesity Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-obesity Medicine industry.
Chapter 3: Detailed analysis of Anti-obesity Medicine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-obesity Medicinerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drugs
- OTC Drugs
Applications
- Men
- Women
Companies covered
- Eisai
- Novo Nordisk
- Merck
- Roche
- Pfizer
- GlaxoSmithKline
- Vivus
- Orexigen Therapeutics
- Boehringer Ingelheim
- Arena Pharmaceuticals
- Amylin Pharmaceuticals
- Alizyme
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Anti-obesity Medicine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Prescription Drugs
- 1.2.3 OTC Drugs
- 1.3 Market Analysis by Application
- 1.3.1 Global Anti-obesity Medicine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Men
- 1.3.3 Women
- 1.4 Global Market Growth Prospects
- 1.5 Global Anti-obesity Medicine Growth Trends by Region
- 1.5.1 Global Anti-obesity Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Anti-obesity Medicine Market Size by Region (2021-2026)
- 1.5.3 Anti-obesity Medicine Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Anti-obesity Medicine Market Dynamics
- 2.1 Anti-obesity Medicine Industry Trends
- 2.2 Anti-obesity Medicine Industry Drivers
- 2.3 Anti-obesity Medicine Industry Opportunities and Challenges
- 2.4 Anti-obesity Medicine Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Anti-obesity Medicine Revenue by Company (2021-2026)
- 3.2 Global Anti-obesity Medicine Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Anti-obesity Medicine Key Company Head office and Area Served
- 3.4 Global Anti-obesity Medicine Company, Product Type & Application
- 3.5 Global Anti-obesity Medicine Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Anti-obesity Medicine Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Anti-obesity Medicine Players Market Share by Revenue in 2025
- 3.6.3 2025 Anti-obesity Medicine Tier 1, Tier 2, and Tier 3
4 Anti-obesity Medicine Market by Type
- 4.1 Global Anti-obesity Medicine Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Anti-obesity Medicine Market Size by Type (2021-2032)
- 4.3 Global Anti-obesity Medicine Market Size Share by Type (2021-2032)
5 Anti-obesity Medicine Market by Application
- 5.1 Global Anti-obesity Medicine Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Anti-obesity Medicine Market Size by Application (2021-2032)
- 5.3 Global Anti-obesity Medicine Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Eisai
- 6.1.1 Eisai Company Information
- 6.1.2 Eisai Business Overview
- 6.1.3 Eisai Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Eisai Anti-obesity Medicine Product Portfolio
- 6.1.5 Eisai Recent Developments
- 6.2 Novo Nordisk
- 6.2.1 Novo Nordisk Company Information
- 6.2.2 Novo Nordisk Business Overview
- 6.2.3 Novo Nordisk Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
- 6.2.5 Novo Nordisk Recent Developments
- 6.3 Merck
- 6.3.1 Merck Company Information
- 6.3.2 Merck Business Overview
- 6.3.3 Merck Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Merck Anti-obesity Medicine Product Portfolio
- 6.3.5 Merck Recent Developments
- 6.4 Roche
- 6.4.1 Roche Company Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Roche Anti-obesity Medicine Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Anti-obesity Medicine Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GlaxoSmithKline
- 6.6.1 GlaxoSmithKline Company Information
- 6.6.2 GlaxoSmithKline Business Overview
- 6.6.3 GlaxoSmithKline Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
- 6.6.5 GlaxoSmithKline Recent Developments
- 6.7 Vivus
- 6.7.1 Vivus Company Information
- 6.7.2 Vivus Business Overview
- 6.7.3 Vivus Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Vivus Anti-obesity Medicine Product Portfolio
- 6.7.5 Vivus Recent Developments
- 6.8 Orexigen Therapeutics
- 6.8.1 Orexigen Therapeutics Company Information
- 6.8.2 Orexigen Therapeutics Business Overview
- 6.8.3 Orexigen Therapeutics Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
- 6.8.5 Orexigen Therapeutics Recent Developments
- 6.9 Boehringer Ingelheim
- 6.9.1 Boehringer Ingelheim Company Information
- 6.9.2 Boehringer Ingelheim Business Overview
- 6.9.3 Boehringer Ingelheim Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
- 6.9.5 Boehringer Ingelheim Recent Developments
- 6.10 Arena Pharmaceuticals
- 6.10.1 Arena Pharmaceuticals Company Information
- 6.10.2 Arena Pharmaceuticals Business Overview
- 6.10.3 Arena Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 6.10.5 Arena Pharmaceuticals Recent Developments
- 6.11 Amylin Pharmaceuticals
- 6.11.1 Amylin Pharmaceuticals Company Information
- 6.11.2 Amylin Pharmaceuticals Business Overview
- 6.11.3 Amylin Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 6.11.5 Amylin Pharmaceuticals Recent Developments
- 6.12 Alizyme
- 6.12.1 Alizyme Company Information
- 6.12.2 Alizyme Business Overview
- 6.12.3 Alizyme Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Alizyme Anti-obesity Medicine Product Portfolio
- 6.12.5 Alizyme Recent Developments
7 North America
- 7.1 North America Anti-obesity Medicine Market Size (2021-2032)
- 7.2 North America Anti-obesity Medicine Market Size by Type
- 7.2.1 North America Anti-obesity Medicine Market Size by Type (2021-2026)
- 7.2.2 North America Anti-obesity Medicine Market Size by Type (2027-2032)
- 7.2.3 North America Anti-obesity Medicine Market Share by Type (2021-2032)
- 7.3 North America Anti-obesity Medicine Market Size by Application
- 7.3.1 North America Anti-obesity Medicine Market Size by Application (2021-2026)
- 7.3.2 North America Anti-obesity Medicine Market Size by Application (2027-2032)
- 7.3.3 North America Anti-obesity Medicine Market Share by Application (2021-2032)
- 7.4 North America Anti-obesity Medicine Market Size by Country
- 7.4.1 North America Anti-obesity Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Anti-obesity Medicine Market Size by Country (2021-2026)
- 7.4.3 North America Anti-obesity Medicine Market Size by Country (2027-2032)
- 7.4.4 North America Anti-obesity Medicine Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Anti-obesity Medicine Market Size (2021-2032)
- 8.2 Europe Anti-obesity Medicine Market Size by Type
- 8.2.1 Europe Anti-obesity Medicine Market Size by Type (2021-2026)
- 8.2.2 Europe Anti-obesity Medicine Market Size by Type (2027-2032)
- 8.2.3 Europe Anti-obesity Medicine Market Share by Type (2021-2032)
- 8.3 Europe Anti-obesity Medicine Market Size by Application
- 8.3.1 Europe Anti-obesity Medicine Market Size by Application (2021-2026)
- 8.3.2 Europe Anti-obesity Medicine Market Size by Application (2027-2032)
- 8.3.3 Europe Anti-obesity Medicine Market Share by Application (2021-2032)
- 8.4 Europe Anti-obesity Medicine Market Size by Country
- 8.4.1 Europe Anti-obesity Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Anti-obesity Medicine Market Size by Country (2021-2026)
- 8.4.3 Europe Anti-obesity Medicine Market Size by Country (2027-2032)
- 8.4.4 Europe Anti-obesity Medicine Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Anti-obesity Medicine Market Size (2021-2032)
- 9.2 China Anti-obesity Medicine Market Size by Type
- 9.2.1 China Anti-obesity Medicine Market Size by Type (2021-2026)
- 9.2.2 China Anti-obesity Medicine Market Size by Type (2027-2032)
- 9.2.3 China Anti-obesity Medicine Market Share by Type (2021-2032)
- 9.3 China Anti-obesity Medicine Market Size by Application
- 9.3.1 China Anti-obesity Medicine Market Size by Application (2021-2026)
- 9.3.2 China Anti-obesity Medicine Market Size by Application (2027-2032)
- 9.3.3 China Anti-obesity Medicine Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Anti-obesity Medicine Market Size (2021-2032)
- 10.2 Asia Anti-obesity Medicine Market Size by Type
- 10.2.1 Asia Anti-obesity Medicine Market Size by Type (2021-2026)
- 10.2.2 Asia Anti-obesity Medicine Market Size by Type (2027-2032)
- 10.2.3 Asia Anti-obesity Medicine Market Share by Type (2021-2032)
- 10.3 Asia Anti-obesity Medicine Market Size by Application
- 10.3.1 Asia Anti-obesity Medicine Market Size by Application (2021-2026)
- 10.3.2 Asia Anti-obesity Medicine Market Size by Application (2027-2032)
- 10.3.3 Asia Anti-obesity Medicine Market Share by Application (2021-2032)
- 10.4 Asia Anti-obesity Medicine Market Size by Country
- 10.4.1 Asia Anti-obesity Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Anti-obesity Medicine Market Size by Country (2021-2026)
- 10.4.3 Asia Anti-obesity Medicine Market Size by Country (2027-2032)
- 10.4.4 Asia Anti-obesity Medicine Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Anti-obesity Medicine Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Anti-obesity Medicine Market Size by Type
- 11.2.1 South America, Middle East & Africa Anti-obesity Medicine Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Anti-obesity Medicine Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Anti-obesity Medicine Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Anti-obesity Medicine Market Size by Application
- 11.3.1 South America, Middle East & Africa Anti-obesity Medicine Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Anti-obesity Medicine Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Anti-obesity Medicine Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Anti-obesity Medicine Market Size by Country
- 11.4.1 South America, Middle East & Africa Anti-obesity Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Anti-obesity Medicine Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Anti-obesity Medicine Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Anti-obesity Medicine Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst